Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers

Journal of Pharmaceutical Sciences

Volumn 93, Issue 8, 2004, Pages 1993-2008

  Wong, Ho Lun ^a   Bendayan, Reina ^a   Rauth, Andrew Mike ^b   Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Anticancer drugs; Chemosensitizers; Controlled release delivery; Doxorubicin; Polymer drug complex; Solid lipid nanoparticles

Indexed keywords

ACETIC ACID; ALGINIC ACID; ANTINEOPLASTIC AGENT; DEXTRAN SULFATE; DICLOFENAC; DOXORUBICIN; NANOPARTICLE; POLYMER; POLYSORBATE 80; PROPRANOLOL; QUINIDINE; SOLID LIPID NANOPARTICLE; STEARIC ACID DERIVATIVE; VERAPAMIL; ZIDOVUDINE;

ARTICLE; CHEMOSENSITIVITY; COMPLEX FORMATION; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; HYDROPHOBICITY; MICROEMULSION; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; ZETA POTENTIAL;

EID: 3843150602     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20100     Document Type: Article

References (39)

1. Balmer CM, Valley AW. 2002. Cancer treatment and chemotherapy. In: Dipiro JT, Talbert RC, Yee GC, Matzke GR, Wells BG, editors. Pharmacotherapy - A pathophysiologic approach, 5th ed. Toronto: Prentice Hall Canada, Inc., pp 2175-2222.
2. Campone M, Vavasseur F, Le Cabellec MT, Meflah K, Vallette FM, Oliver L. 2001. Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein. Leukemia 15:1377-1387.
3. Abolhoda A, Wilson A, Ross H, Danenberg P, Burt M, Scotto K. 1999. Rapid activation of MDR1 gene expression in human metastic sarcoma after in vivo eposure to doxorubicin. Clin Cancer Res 5:3352-3356.
4. Volm M. 1998. Multidrug resistance and its reversal. Anticancer Res 18:2905-2918.
5. Vezmar M, Georges E. 2000. Reversal of MDR-mediated doxorubicin resistance with quinolone-based drugs. Biochem Pharmacol 59:1245-1252.
6. Teodori E, Dei S, Scapecchi S, Gualtieri F. 2002. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 57: 385-415.
7. Belpomme D, Gauthier S, Pujade-Lauraine E. 2000. Verapamil increases the survival of patients with anthracycline-resistant metastic breast carcinoma. Ann Oncol 11:1417-1476.
8. Aszalos A, Ladanyi A, Bocsi J, Szende B. 2001. Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators. Cancer Lett 167:157-162.
9. Merlin J, Bour-Dill C, Marchal S, Ramacci C, Poullain M, Giroux B. 2000. Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles. Cytometry 41:62-72.
10. Huang M, Ahm CH, Pine PS, Yin JJ, Hrycyna CA, Licht T, Aszalos A. 1996. Effect of combinations of suboptimal of P-glycoprotein blockers on the proliferation of MDR gene expressing cells. Int J Cancer 65:389-397.
11. Kim CK, Lim SJ. 2002. Recent progress in drug delivery systems for anticancer agents. Arch Pharm Res 25:229-239.
12. Soma CE, Dubernet C, Bentotila D, Benita S, Couvreur P. 2000. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21:1-7.
13. Soma CE, Dubernet C, Barratt G, Nemati F, Appel M, Benita S, Couvreur P. 1999. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res 16:1710-1716.
14. Hu YP, Jarillon S, Dubernet C, Couvreur P, Robert J. 1996. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother Pharmacol 37:556-560.
15. Emerich DR, Snodgrass P, Lafreniere D, Dean RL, Salzberg H, Marsh J, Perdomo B, Arastu M, Winn SR, Bartus RT. 2002. Sustained release chemotherapeutic microspheres provides superior efficacy over systemic therapy and local bolus infusions. Pharm Res 19:1052-1060.
16. Mehnert W, Mader K. 2001. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47:165-196.
17. Muller RH, Karsten M, Sven G. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm 50:161-177.
18. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W. 1997. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfacant. Pharm Res 14:458-462.
19. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. 2000. Nano-stealth and stealth solid lipid nanoparticles (sln) carrying doxorubicin: Pharmacokinetics and tissue distribution after iv administration to rats. Pharm Res 42:337-343.
20. zur Muhlen A, Schwarz C, Mehnert W. 1997. Solid lipid nanoparticles (sln) for controlled drug delivery - Drug release and release mechanism. Eur J Pharm Biopharm 45:149-155.
21. Liu Z, Wu XY, Bendayan R. 1999. In vitro investigation of ionic polysaccharide microspheres for simultaneous delivery of chemosensitizer and antineoplastic agent to multidrug-resistant cells. J Pharm Sci 88:412-418.
22. Liu Z, Bendayan R, Wu XY. 2001. Triton-X-100-modified polymer and microspheres for reversal of miltidrug resistance. J Pharm Pharmacol 53: 1-12.
23. Liu Z, Cheung R, Bendayan R, Ballinger J, Rauth M, Wu XY. 2001. A study of doxorubicin loading onto and release from sulfopropyl dextran ion-exchange microspheres. J Controlled Release 77: 213-224.
24. Liu Z, Ballinger J, Rauth M, Bendayan R, Wu XY. 2003. Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres. J Pharm Pharmacol 55:1063-1073.
25. Hagiwara A, Sakakura C, Yamasaki J, Togawa T, Sonoyama Y, Fujiyama J, Yamagishi H. 2000. Dextran sulfate inhibits injured abdominal wall-specific tumor implantation in mice. Anticancer Drugs 11:873-877.
26. Hagiwara A, Sakakura C, Shirasu M, Togawa T, Sonoyama Y, Fujiyama J, Ebihara Y, Itoh T, Yamagishi H. 2000. Intraperitoneal injection of dextran sulfate as an anti-adherent drug for the prevention of peritoneal metastasis of cancer shows low toxicity in animals. Anti-Cancer Drugs 11:393-399.
27. Yamazaki T, Sato Y, Hanai M, Mochimaru J, Tsujino I, Sawada U, Horie T. 2000. Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx. Cancer Lett 149: 153-161.
28. Ellis AG, Crinis NA, Webster LK. 1996. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 38:81-87.
29. Aquilano D, Cavalli R, Gasco MR. 1993. Solid lipospheres obtained from hot microemulsion in the presence of different concentrations of cosurfactant: The crystallization of stearic acid polymorphs. Thermochim Acta 230:29-37.
30. Yoo HS, Oh JE, Lee KH, Park TG. 1999. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res 16:1114-1118.
31. Heiati H, Tawashi R, Shivers RR, Phillips NC. 1997. Solid lipid nanoparticles as drug carriers I - Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate. Int J Pharm 146:123-131.
32. Pietzonka P, Rothen-Rutishauser B, Langguth P, Wunderli-Allenspach H, Walter E, Merkle HP. 2002. Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake. Pharm Res 19:595-601.
33. Muller RH, Radtke M, Wissing SA. 2002. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121-128.
34. Ikom F, Hanna GK, Schmid-Schombein GW. 1999. Size- and surface-dependent uptake of colloid particle into the lymphatic system. Lymphology 32:90-102.
35. Mazer NA. 1985. Laser light scattering in micellar systems. In: Pecora R, editor. Dynamic Light scattering. New York: Plenum Inc., chap. 8, p 305.
36. Isojima T, Fuji S, Kubota K, Hamano K. 2000. Double critical behavior and micellar size effect in the multicomponent surfactant solution. J Chem Phys 113:3916-3925.
37. Blokhuis EM, Sager WFC. 2001. Sphere to cylinder transition in a single phase microemulsion system: A theoretical investigation. J Chem Phys 115: 1073-1085.
38. Hahn SM, Russo A, Cook HA, Mitchell JB. 1999. A multidrug-resistant breast cancer line induced by weekly exposure to doxorubicin. Int J Oncol 14: 273-279.
39. Chaudhary PM, Roninson IB. 1993. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein-kinase-C agonist. Oncol Res 4:281.